PXMD Stock Overview
A clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
PaxMedica, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.30 |
52 Week High | US$25.50 |
52 Week Low | US$0.20 |
Beta | 0 |
1 Month Change | -60.12% |
3 Month Change | -48.28% |
1 Year Change | -98.77% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.64% |
Recent News & Updates
Shareholder Returns
PXMD | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 13.9% | 1.9% | 1.2% |
1Y | -98.8% | 16.7% | 27.7% |
Return vs Industry: PXMD underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: PXMD underperformed the US Market which returned 27.7% over the past year.
Price Volatility
PXMD volatility | |
---|---|
PXMD Average Weekly Movement | 38.4% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PXMD's share price has been volatile over the past 3 months.
Volatility Over Time: PXMD's weekly volatility has increased from 28% to 38% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 7 | Howard Weisman | www.paxmedica.com |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT.
PaxMedica, Inc. Fundamentals Summary
PXMD fundamental statistics | |
---|---|
Market cap | US$2.22m |
Earnings (TTM) | -US$18.15m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs PXMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PXMD income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$18.15m |
Earnings | -US$18.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.43 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did PXMD perform over the long term?
See historical performance and comparison